Have a personal or library account? Click to login
Biosimilar medical products – licensing, pharmacovigilance and interchangeability Cover

Biosimilar medical products – licensing, pharmacovigilance and interchangeability

PRILOZI
Volume 37 (2016): Issue 1 (June 2016)
By: Aleksandra Grozdanova,  Katerina Ancevska Netkovska,  Zoran Sterjev,  Zorica Naumovska,  Rubin Zarevski,  Aleksandar Dimovski and  Ljubica Suturkova  
Open Access
|Jul 2016

References

  1. 1. Dolinar RO, Reilly MS. The future of biological therapy: a pathway forward for biosimilars. GaBI Journal. 2013; 2(1): 36–40.10.5639/gabij.2013.0201.014
    Search in Google Scholar
  2. 2. Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012; 11 (7): 527–540.10.1038/nrd3746371437022743980
    Search in Google Scholar
  3. 3. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood 2012; 120 (26): 5111–5117.10.1182/blood-2012-04-42574423093622
    Search in Google Scholar
  4. 4. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev. 2007; 28: 625–652.10.1210/er.2007-000217785428
    Search in Google Scholar
  5. 5. EMA/CHMP/437/04 Rev 1. Guideline on Similar Biological Medicinal Products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf.
    Search in Google Scholar
  6. 6. FDA. Information for Consumers (Biosimilars). Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approval/Applications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm.
    Search in Google Scholar
  7. 7. WHO Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/areas/biological_therapeutics,Biotherapeuticsforweb_22april2010.pdf.
    Search in Google Scholar
  8. 8. Health Canada. Fact Sheet: Subsequent Entry Biologics in Canada. Available at: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/fs-fi/fs-fi_seb-pbu_07–2006-eng.php.
    Search in Google Scholar
  9. 9. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel). 2012; 5(4): 353–368.10.3390/ph5040353376364424281406
    Search in Google Scholar
  10. 10. EMA. Guideline on similar biological medicinal products. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2009/09/WC500003517.pdf.
    Search in Google Scholar
  11. 11. EMA. Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies—Non-clinical and Clinical Issues. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2012/06/WC500128686.pdf
    Search in Google Scholar
  12. 12. EMA. Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use. 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/scientific_guideline/2012/06/WC500128688.pdf
    Search in Google Scholar
  13. 13. EMA. Guideline on Good Pharmacovigilance Practices. 2013 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142282.pdf
    Search in Google Scholar
  14. 14. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. European Commission. Available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_report_en.pdf.
    Search in Google Scholar
  15. 15. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011; 3: 209–217.10.4161/mabs.3.2.15005309262221441787
    Search in Google Scholar
  16. 16. EMA. Guideline on Similar Biological Medicinal Products. 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC50017.pdf
    Search in Google Scholar
  17. 17. Scott C. A decade of process development. BioProcess Int. 2012; 10: 72–78.
    Search in Google Scholar
  18. 18. World Health Organization Executive Summary. Proceedings of the 55th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 16-18 October 2012. www.who.int/medicines/services/inn/55th_Executive_Summary.pdf.
    Search in Google Scholar
  19. 19. Silverman E. Biosimilars: what’s in a name? BMJ 2014; 348: g27210.1136/bmj.g27224443479
    Search in Google Scholar
  20. 20. Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, Warnock DG. Pharmacovigilance and biosimilars: considerations, needs, and challenges. Expert Opin Biol Ther 2013; 13: 1039–47.10.1517/14712598.2013.78356023527621
    Search in Google Scholar
  21. 21. The Pharmaceuticals and Medical Devices Agency, Japan. March 2009 Guideline for the Quality, Safety, and Effectiveness of Biosimilar Products. Tokyo: Pharmaceuticals and Medical Devices Agency.
    Search in Google Scholar
  22. 22. World Health Organization. Apr 2009. Guidelines on Evaluation of Similar Biotherapeutic Products. Geneva: World Health Organization Expert Committee on Biological Standardization.
    Search in Google Scholar
  23. 23. World Health Organization. Jan 2014. Regulatory Expectations and Risk Assessment for Biotherapeutic Products: Scientific Principles to Consider.
    Search in Google Scholar
  24. 24. European Generic Medicines Association. Biosimilars Handbook, 2nd ed. 2011, Brussels: European Generic Medicines Association.
    Search in Google Scholar
  25. 25. Dörner T, Strand V, Castañeda-Hernández G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 72: 322–328.10.1136/annrheumdis-2012-20271523253920
    Search in Google Scholar
  26. 26. EMA. Questions and Answers on Biosimilar Medicines, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf.
    Search in Google Scholar
  27. 27. Rovira, J, Espin J, Garcia L, Olry de Labry A. The Impact of Biosimilars’ Entry in the EU Market. Andalusian School of Public Health. 2011. Available at: http://citeseerx.ist.psu.edu/viewdoc/download?doi510.1.1.357.2218&rep5rep1&type5.pdf.
    Search in Google Scholar
  28. 28. Jelkmann W. Biosimilar epoetins and other “follow-on” biologics: update on the European experiences. Am J Hematol. 2010; 85: 771–780.10.1002/ajh.2180520706990
    Search in Google Scholar
  29. 29. France to allow biosimilars substitution. 2014. Available at: http://www.gabionline.net/Policies-Legislation/France-to-allow-biosimilars-substitution/(highlight)/france%20substitution.
    Search in Google Scholar
  30. 30. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood. 2014; 124: 3191–3196.10.1182/blood-2014-06-58361725298038
    Search in Google Scholar
DOI: https://doi.org/10.1515/prilozi-2016-0006 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Journal RSS Feed
Language: English
Page range: 27 - 36
Published on: Jul 15, 2016
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Regulatory,
biosimilars,
biologics,
licensing,
interchangeability,
pharmacovigilance,
EMA
Related subjects:
Medicine,
Basic medical science,
History and ethics of medicine,
Clinical medicine,
Clinical medicine, other,
Social sciences,
Education,
Education, other

© 2016 Aleksandra Grozdanova, Katerina Ancevska Netkovska, Zoran Sterjev, Zorica Naumovska, Rubin Zarevski, Aleksandar Dimovski, Ljubica Suturkova, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 37 (2016): Issue 1 (June 2016)Next article